Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing a novel antithrombotic in the academic environment.

J Hirsh1

  • 1Hamilton Civic Hospital Research Center and McMaster University, Hamilton, Ontario, Canada.

Seminars in Hematology
|July 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.

Annals of internal medicine·1997
Same author

Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.

Circulation·1997
Same author

Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study.

Circulation·1996
Same author

Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.

Haemostasis·1996
Same author

Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo.

Blood·1996
Same author

The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.

Archives of internal medicine·1996

Hamilton Civic Hospitals Research Center is commercializing discoveries in thrombosis and osteoporosis through new companies. These ventures aim to develop promising drug candidates for significant unmet medical needs.

Area of Science:

  • Biotechnology
  • Pharmaceutical Sciences
  • Medical Research Commercialization

Background:

  • Academic institutions are increasingly commercializing research discoveries to secure funding and financial benefits.
  • Hamilton Civic Hospitals Research Center has established two companies, Vascular Therapeutics and Osteokine, to commercialize innovations in thrombosis and osteoporosis.
  • Thrombosis and osteoporosis represent significant socioeconomic burdens, highlighting the need for novel therapeutic interventions.

Purpose of the Study:

  • To describe the commercialization efforts of Hamilton Civic Hospitals Research Center in the fields of thrombosis and osteoporosis.
  • To identify key areas for drug development in thrombosis, including anticoagulants and antiplatelet agents.
  • To highlight the progress and potential of newly formed companies in translating research into clinical and commercial products.

Related Experiment Videos

Main Methods:

  • Establishment of spin-off companies (Vascular Therapeutics and Osteokine) to manage commercialization.
  • Focus on developing novel drug candidates for thrombosis and osteoporosis.
  • Attracting venture capital and developing patentable compounds.

Main Results:

  • Vascular Therapeutics and Osteokine have successfully attracted substantial funding.
  • Several patentable compounds with clinical and commercial promise have been developed.
  • The commercialization strategy addresses critical therapeutic needs in thrombosis and osteoporosis.

Conclusions:

  • The commercialization of academic research through dedicated companies can accelerate the development of new therapies.
  • Hamilton Civic Hospitals Research Center's initiatives demonstrate a successful model for translating scientific discoveries into potential treatments for major diseases.
  • Investment in and development of novel compounds for thrombosis and osteoporosis hold significant clinical and economic potential.